Vaccines Redefined

Investors

Press Release Archive

• 08/09/2010
  AlphaVax’s Vector System Shows Potential for Cancer Immunotherapy click here >>
  
• 01/19/2010
  AlphaVax Advances Filovirus Biodefense Vaccines click here >>
  
• 09/01/2009
  AlphaVax Progresses H1N1 Influenza Vaccine click here >>
• 07/17/2009
  AlphaVax Announces Results from Initial Testing of its H1N1 (Swine) Influenza Vaccine click here >>
  
• 05/28/2009
  2009 IBC Meeting click here >>
  
• 05/14/2009
  AlphaVax Announces Phase I/II Study of Active Cancer Immunotherapy click here >>
  
• 05/13/2009
  AlphaVax Announces Promising Results in Melanoma Studies click here >>
  
• 02/16/2009
  AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations click here >>
  
• 12/29/2008
  Novartis enters into exclusive agreement with AlphaVax for novel CMV vaccine candidate click here >>
  
• 10/29/2008
  AlphaVax Presents Results from CMV Phase 1 Trial click here >>
  
• 07/21/2008
  AlphaVax Announces Initiation of Chlamydia Vaccine Program click here >>
  
• 06/06/2008
  AlphaVax Continues to Expand the Use of its Vaccine Platform click here >>
  
• 04/17/2008
  AlphaVax Announces Initial Analysis of Data from CMV Phase 1 Clinical Trial click here >>
  
• 01/30/2008
  AlphaVax Announces New CMV Advisory Board click here >>
  
• 10/31/2007
  AlphaVax Announces Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
  
• 07/30/2007
  AlphaVax Announces Interim Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
  
• 07/10/2007
  AlphaVax Announces $3.6M Award to Develop New Adjuvant Technologies for Vaccines click here >>
  
• 04/11/2007
  AlphaVax begins Clinical Trials with Vaccines for CMV and FLU click here >>
  
• 03/13/2007
  In The Pipeline click here >> 02/19/2007 New Data Support AlphaVax's Vaccine for CMV click here >>
  
• 02/02/2007
  AlphaVax Announces the Closing of its E Series Investment Offering click here >>
  
• 01/29/2007
  AlphaVax Announces Clinical Trials for Influenza and CMV click here >>
  
• 10/11/2006
  Parents of EEE victim raising money for disease research click here >>
  
• 09/06/2006
  AlphaVax Announces Phase 1 Clinical Trial Results click here >>
  
• 07/26/2006
  AlphaVax Granted Key Vaccine Manufacturing Patent in US click here >>
  
• 05/10/2006
  Three NCBIO members serving on National BIO Committees click here >>
  
• 04/05/2006
  Peter Young to Testify on BioShield click here >>
  
• 11/11/2005
  The Triangle’s Fastest Growing Private Biotech Company click here >>
  
• 10/21/2005
  Alphavax Announces Support of Senator Richard Burr's Legislation click here >>
  
• 10/19/2005
  Alphavax Announces $3.3 Million Grant Award to Develop A Smallpox Vaccine click here >>
  
• 06/03/2005
  AlphaVax Announces New Lease for Vaccine Manufacturing Operations click here >>
  
• 05/01/2005
  Peter Young elected Chair of NCBIO click here >>
  
• 04/10/2005
  AlphaVax Annouces NIH Award for Influenza Vaccine click here >>
  
• 02/06/2005
  Gene Vaccine Protects Mice Against Development of Her2/neu Breast Cancer click here >>
  
• 11/17/2004
  AlphaVax Annouces $4.8m Award for a SARS Vaccine click here >>
  
• 06/04/2004
  AlphaVax Annouces New Vice President of Development click here >>
  
• 03/25/2004
  AlphaVax Annouces New Manufacturing Initiative click here >>
  
• 11/19/2003
  AlphaVax Names Jonathan Smith Chief Scientific Officer click here >>
  
• 10/21/2003
  AlphaVax Annouces New $16.8 Million NIH Award click here >>
• 09/05/2003
  AlphaVax Receives Two NIH Biodefense Grants click here >>
• 08/22/2003
  AlphaVax Begins Human Clinical Trials of Novel Vaccine Technology click here >>
  
• 07/12/2003
  Progenics and Cytogen Develop Novel Prostate Cancer Vaccine with AlphaVax click here >>
  
• 06/26/2003
  AlphaVax Hires New Medical Director click here >>
  
• 05/15/2003
  AlphaVax Annouces New Head of Discovery and New Facility click here >>
  
• 04/03/2002
  AlphaVax Annouces $11 million in Series C click here >>
  
• 03/04/2002
  AlphaVax signs Manufacturing Agreement click here >>
  
• 02/28/2001
  AlphaVax announces $8.2 million in Series B click here >>
  
• 02/03/2001
  Glaxo Wellcome VP, Peter F. Young, named as President of AlphaVax click here >>
  
• 11/19/2000
  International AIDS Vaccine Initiative Announces Major Research Partnership with AlphaVax click here >>